← Return to Good PSA/MRI active surveillance results still require fusion biopsy?

Discussion

Good PSA/MRI active surveillance results still require fusion biopsy?

Prostate Cancer | Last Active: Nov 26, 2024 | Replies (31)
Comment receiving replies
@jeffmarc

I don’t know the answer to that, but I would contact them to get more information..

Jump to this post

Replies to "I don’t know the answer to that, but I would contact them to get more information.."
bens1 | @bens1 | Oct 18, 2024

@jeffmarc
I just contacted them and got a quick answer regarding the MPS2 test. They said:

"MPS 2.0 does not identify the biological recurrence of prostate cancer.

MPS 2.0 is a non-invasive urine test that analyzes 18 unique biomarkers and accurately quantifies the personalized risk of clinically significant prostate cancer (csPCa) for men with elevated PSA or abnormal DRE findings. The test results offer you and your Urologist the clear, accurate insights you need to decide the next clinical steps.

Researchers are studying the utility of MPS 2.0 in patients on active surveillance and in patients newly diagnosed with prostate cancer considering active surveillance.

However, MPS 2.0 was developed and validated in patients not previously diagnosed with prostate cancer. Therefore, it has not been evaluated in patients on active surveillance and should not be used in these cases."

VIEW AND REPLY